PMV Pharmaceuticals (PMVP) Cash from Investing Activities (2019 - 2026)

PMV Pharmaceuticals (PMVP) has 8 years of Cash from Investing Activities data on file, last reported at $20.8 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 27.48% year-over-year to $20.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $62.3 million (up 11.42% YoY) and the FY2025 annual result came in at $70.2 million, up 31.53% from the prior year.
• Cash from Investing Activities advanced to $20.8 million in Q1 2026, from $18.4 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $49.6 million in Q1 2023 to a low of -$64.0 million in Q2 2023.
• A 5-year average of $5.4 million and a median of $12.0 million in 2025 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities soared 4358.73% — and 2023, when it plunged 318.63%.
• Tracing PMVP's Cash from Investing Activities over 5 years: stood at $23.2 million in 2022, then slumped by 111.14% to -$2.6 million in 2023, then jumped by 399.23% to $7.7 million in 2024, then jumped by 138.17% to $18.4 million in 2025, then advanced by 12.9% to $20.8 million in 2026.
• The last three Cash from Investing Activities figures came in at $20.8 million (Q1 2026), $18.4 million (Q4 2025), and $12.0 million (Q3 2025), per Business Quant data.